Phase 3 Trials

Apogee Secures $1.3 Billion Blackstone Package and Selects Mid‑Dose After Positive Phase 2

The company says the deal plus roughly $1.3 billion in cash should fund late‑stage development through potential approval with Blackstone taking tiered royalties on future sales.